{
    "2021-10-31": [
        [
            {
                "time": "",
                "original_text": "西部证券维持贝达药业买入评级，2021年三季报点评：埃克替尼稳定增长，恩沙替尼放量待推进",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "买入评级",
                        "2021年三季报",
                        "埃克替尼",
                        "稳定增长",
                        "恩沙替尼",
                        "放量待推进"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}